Theriva Biologics (TOVX) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 49.5% versus a loss of 93.9%. Over five years, VTGN leads with a -99.7% price change compared with -99.8% for TOVX. Vistagen Therapeutics is the larger company by market cap ($10.6 million vs $10.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TOVX | VTGN |
|---|---|---|
| Share price | $0.2211 | $0.2383 |
| Market cap | $10.15M | $10.58M |
| 1-day change | -2.64% | -3.21% |
| YTD return | +8.14% | -62.70% |
| 1-year return | -49.53% | -93.88% |
| 5-year return | -99.79% | -99.66% |
| P/E ratio (TTM) | 0.30 | — |
| EPS (TTM) | $0.73 | $-1.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $0.86 | $5.14 |
| 52-week low | $0.16 | $0.20 |
| Distance from 52-week high | -74.29% | -95.36% |
| Analyst consensus | none | none |
| Avg. price target upside | +1030.71% | +319.64% |
| Average volume | 525.96K | 12.36M |
| Shares outstanding | 45.89M | 44.38M |
| Employees | 15 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed VTGN by 44.3 percentage points over the past year.
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
TOVX vs VTGN FAQ
Which is bigger, Theriva Biologics or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $10.58M compared with $10.15M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, TOVX or VTGN?
TOVX returned -49.53% over the past 12 months, compared with -93.88% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Theriva Biologics and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.